Aligned with U.S. Food and Drug Administration (FDA) on Registrational Path for RE104 in Postpartum Depression (PPD); On Track to Initiate ...

At Praxis, Dr. Devinsky will be part of the group leading clinical strategy and global medical affairs, guiding program architecture, evidence generation, and external scientific engagement as the ...

Vigil Neuroscience, Inc. has announced its financial results for Q1 2025 and provided updates on its clinical trials. The company is on track to report the final analysis from its Phase 2 IGNITE trial ...

SAN DIEGO--(BUSINESS WIRE)--Nuvie Bio, a new clinical-stage biopharmaceutical company dedicated to addressing the most pressing unmet medical needs in migraine and related neurological diseases, ...

TORONTO, Ontario and CAMBRIDGE, Massachusetts, Nov. 20, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (PMN), a biotechnology company focused on the generation and development of antibody ...

Cumulus Neuroscience, a leading innovator in brain health technology for clinical trials, today announced the publication of ...

Clinical trial organization Tekton Research has added a new site embedded inside New Carlisle Family Practice to expand neuroscience and general medicine capabilities, as well as deepen access to ...

CAMBRIDGE, Massachusetts, Jan. 10, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative ...

A study published in Journal of Neuropsychiatry and Clinical Neuroscience observed the efficacy of donepezil for addressing persistent verbal memory impairments among individuals with predominantly ...

Indian American physician to help accelerate commercial readiness for biotechnology firm’s cell therapy for Parkinson’s ...

ProMIS Neurosciences, a clinical-stage biotechnology company focused on developing therapeutic antibodies for neurodegenerative diseases, has announced a purchase agreement to issue approximately $2.4 ...

"It has been a pleasure to be associated with Cumulus for the last 6 years, as founder, chair and keen supporter," said Ruth McKernan, Co-founder of Cumulus. "As my term comes to an end, I wish ...